Literature DB >> 25301329

Renal risk and response in amyloidosis.

Angela Dispenzieri1.   

Abstract

In this issue of Blood, Palladini and colleagues address incidence of and risk factors for end-stage renal disease (ESRD) and proffer a new renal response system for patients with amyloid light-chain (AL) amyloidosis using a test set of 461 patients from Pavia, Italy, and a validation set of 271 patients from Heidelberg, Germany. Validation of organ response criteria has trailed behind the progress made in the field of AL amyloidosis in diagnosis, prognosis, and hematologic response, but Palladini and colleagues' study helps breach this gap.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25301329     DOI: 10.1182/blood-2014-08-596338

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  4 in total

1.  Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation.

Authors:  Andrea Havasi; Lauren Stern; Stephen Lo; Fangui Sun; Vaishali Sanchorawala
Journal:  Am J Hematol       Date:  2016-07-14       Impact factor: 10.047

2.  Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation.

Authors:  Andrea Havasi; Gheorghe Doros; Vaishali Sanchorawala
Journal:  Am J Hematol       Date:  2018-02-24       Impact factor: 10.047

3.  Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.

Authors:  Roberta Fenoglio; Simone Baldovino; Michela Ferro; Savino Sciascia; Gianluca Rabajoli; Giacomo Quattrocchio; Giulietta Beltrame; Carla Naretto; Daniela Rossi; Mirella Alpa; Antonella Barreca; Mario Giulio Papotti; Dario Roccatello
Journal:  J Nephrol       Date:  2020-05-29       Impact factor: 3.902

Review 4.  CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond.

Authors:  Dario Roccatello; Roberta Fenoglio; Savino Sciascia; Carla Naretto; Daniela Rossi; Michela Ferro; Antonella Barreca; Fabio Malavasi; Simone Baldovino
Journal:  Int J Mol Sci       Date:  2020-06-10       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.